Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Chardan Capital in a research note issued on Tuesday, Benzinga reports. They currently have a $30.00 price objective on the stock. Sonnet BioTherapeutics Stock Up 1.9 % Shares of Sonnet BioTherapeutics stock opened at $1.65 on Tuesday. The firm’s […]